GEO DataSets for BioProject (Select 196517) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from BioProject

Items: 3

Select item 2000458671.

Effects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium

(Submitter supplied) Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we investigated the global molecular effects of Tocilizumab, an approved humanized anti-IL6 Receptor antibody, versus Methotrexate therapy, in synovial biopsy samples collected prospectively in early RA before and 12 weeks after administration of the drug. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Datasets:: GDS5068 GDS5069
Platform:: GPL570
40 Samples

Download data: CEL

Series

Accession:: GSE45867

ID:: 200045867

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 50692.

Rheumatoid arthritic synovium response to methotrexate

Analysis of synovial biopsies from rheumatoid arthritis patients before and 12 weeks after the start of methotrexate (MTX) therapy. Results compared to those obtained from tocilizumab (TCZ) therapy (GDS5068) and provide insight into the differences in the mechanisms of action between TCZ and MTX.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 2 agent, 8 individual sets

Platform:: GPL570
Series:: GSE45867
16 Samples

Download data: CEL

DataSet

Accession:: GDS5069

ID:: 5069

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 50683.

Rheumatoid arthritic synovium response to tocilizumab

Analysis of synovial biopsies from rheumatoid arthritis patients before and 12 weeks after the start of tocilizumab (TCZ) therapy. Results compared to those obtained from methotrexate (MTX) therapy (GDS5069) and provide insight into the differences in the mechanisms of action between TCZ and MTX.